CMS: Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment

Ruxolitinib phosphate cream is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo. It is also the first drug specifically for repigmentation in non-segmental vitiligo, filling a decades-long void in the field and offering new hope for patients.   China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Rxilient Medical received approval from the Health Sciences Authority of Singapore (HSA) on 3 November 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product” or “Lumirix®”) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. It is the first and only topical prescription drug in Singapore that directly targets the pathophysiological mechanism of vitiligo[1], meeting a long-standing unmet clinical need. This approval fills a gap in the field of vitiligo treatment in Singapore. In addition to Singapore, Rxilient Medical has already launched sales of […]